JP2025513720A - 多発性硬化症及び抗ＭＯＧ抗体性疾患のための新規治療法としてのＭＨＣ Ｉｂ仲介ミエリン特異的免疫抑制 - Google Patents

多発性硬化症及び抗ＭＯＧ抗体性疾患のための新規治療法としてのＭＨＣ Ｉｂ仲介ミエリン特異的免疫抑制 Download PDF

Info

Publication number
JP2025513720A
JP2025513720A JP2024556457A JP2024556457A JP2025513720A JP 2025513720 A JP2025513720 A JP 2025513720A JP 2024556457 A JP2024556457 A JP 2024556457A JP 2024556457 A JP2024556457 A JP 2024556457A JP 2025513720 A JP2025513720 A JP 2025513720A
Authority
JP
Japan
Prior art keywords
seq
recombinant polypeptide
domain
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513720A5 (https=
Inventor
ブルッテル，ヴァレンティン
ヴィシュフーゼン，イェルク
ブリュンネルト，ダニエラ
アーサン，ファディル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of JP2025513720A publication Critical patent/JP2025513720A/ja
Publication of JP2025513720A5 publication Critical patent/JP2025513720A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024556457A 2022-03-24 2023-03-24 多発性硬化症及び抗ＭＯＧ抗体性疾患のための新規治療法としてのＭＨＣ Ｉｂ仲介ミエリン特異的免疫抑制 Pending JP2025513720A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22164122.8 2022-03-24
EP22164122 2022-03-24
PCT/EP2023/057679 WO2023180546A1 (en) 2022-03-24 2023-03-24 Mho ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease

Publications (2)

Publication Number Publication Date
JP2025513720A true JP2025513720A (ja) 2025-04-30
JP2025513720A5 JP2025513720A5 (https=) 2026-03-12

Family

ID=81389016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556457A Pending JP2025513720A (ja) 2022-03-24 2023-03-24 多発性硬化症及び抗ＭＯＧ抗体性疾患のための新規治療法としてのＭＨＣ Ｉｂ仲介ミエリン特異的免疫抑制

Country Status (12)

Country Link
US (1) US20250222083A1 (https=)
EP (1) EP4499676A1 (https=)
JP (1) JP2025513720A (https=)
KR (1) KR20240162578A (https=)
CN (1) CN118922435A (https=)
AU (1) AU2023240382A1 (https=)
CA (1) CA3255287A1 (https=)
CL (1) CL2024002837A1 (https=)
CO (1) CO2024013220A2 (https=)
IL (1) IL315510A (https=)
MX (1) MX2024011667A (https=)
WO (1) WO2023180546A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061913A1 (en) * 2023-09-22 2025-03-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630809A1 (en) 2017-05-23 2020-04-08 Bruttel, Valentin Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
US11464840B2 (en) * 2018-02-26 2022-10-11 Swey-Shen Chen Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers

Also Published As

Publication number Publication date
US20250222083A1 (en) 2025-07-10
CL2024002837A1 (es) 2025-02-21
EP4499676A1 (en) 2025-02-05
AU2023240382A1 (en) 2024-11-14
CO2024013220A2 (es) 2024-10-31
CA3255287A1 (en) 2023-09-28
CN118922435A (zh) 2024-11-08
KR20240162578A (ko) 2024-11-15
WO2023180546A1 (en) 2023-09-28
IL315510A (en) 2024-11-01
MX2024011667A (es) 2024-09-27
WO2023180546A8 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
TW202208413A (zh) 用於治療多發性硬化症之肽及方法
KR20210041559A (ko) 다발경화증에서의 면역우세 단백질 및 단편
TW201130972A (en) Modified MELK peptides and vaccines containing the same
JP2025513720A (ja) 多発性硬化症及び抗ＭＯＧ抗体性疾患のための新規治療法としてのＭＨＣ Ｉｂ仲介ミエリン特異的免疫抑制
JP2026065089A (ja) Ｄｃａｆ４ｌ２特異的ｔ細胞受容体
CN111138521B (zh) 源自于afp抗原的短肽
US20250205322A1 (en) Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
CN106478797B (zh) 源自于sage1的肿瘤抗原短肽
CN107936109A (zh) 衍生自sage1的肿瘤抗原短肽
TW202519540A (zh) MHC Ib媒介之髓磷脂特異性免疫抑制作為用於多發性硬化症及MOG抗體疾病之新穎治療
JP2025510149A (ja) １型糖尿病の新規治療法としてのＭＨＣ Ｉｂ仲介膵島抗原特異的免疫抑制
CN108218977A (zh) 源自于肿瘤抗原sage1的短肽
TW202530251A (zh) ＭＨＣ Ｉｂ媒介之水通道蛋白４（ＡＱＰ４）特異性免疫抑制作為用於ＮＭＯ之新穎治療
CN112300261B (zh) 一种衍生自afp的肿瘤抗原短肽
CN111138522B (zh) 衍生自afp的肿瘤抗原短肽
CN110862449B (zh) 衍生自ssx的肿瘤抗原短肽
CN118852387A (zh) 源自于mage a4的肿瘤抗原肽及其复合物
CN118852386A (zh) 一种衍生自mage a4的肽及其复合物
CN108250286A (zh) 源自于pasd1的肿瘤抗原短肽
CN108218976A (zh) 衍生自lmp1的肿瘤抗原短肽
JP2011116719A (ja) Ｈｌａ−ｄｒ４エピトープの同定と、関節炎治療への応用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241008

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20241008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260304